ClinicalTrials.gg
TerminatedNCT00756041Updated Feb 28, 2012

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

A Phase 2 interventional study of TAK-128 in Diabetic Neuropathies, sponsored by Takeda. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-28.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of Efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
221
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to determine the safety of TAK-128, once daily (QD), for treatment of diabetic peripheral neuropathy

Read the detailed description

Polyneuropathy is a frequent complication of diabetes; it affects most individuals after prolonged hyperglycemia, and diabetic neuropathy is very common in the developed world. Chronic, insidious, distal sensorimotor polyneuropathy with autonomic impairment is the most typical form of diabetic neuropathy. Less common, but more florid presentations include autonomic symptoms or painful neuropathy. Although many patients have no or relatively few symptoms, the chronic polyneuropathy and autonomic dysfunction predispose to neurotrophic foot ulceration; consequently, diabetes is the leading cause of amputation today.

Diabetic neuropathy is a dying-back polyneuropathy with distal degeneration of the longest nerve fibers advancing in a centripetal direction. Multiple histopathological changes are observed, but progressive fiber loss is the hallmark of diabetic polyneuropathy. Other important features include endothelial cell basement membrane thickening, segmental demyelination and remyelination, and axonal atrophy. Similar pathological changes are observed in type 1 and type 2 diabetes. The severity of neuropathy as indicated by the stage of nerve fiber loss determines the clinical, electrophysiological, and quantitative sensory threshold features of this disorder. The functional measures of electrophysiological and quantitative sensory thresholds reflect the morphological changes and the clinical features.

Diabetic polyneuropathy is etiologically related to prolonged hyperglycemia with multiple consequences. Although strict glycemic control prevents neuropathy in type 1 patients if maintained for many years, similar interventions in those with type 2 diabetes mellitus are less successful. Type 2 patients may have neuropathy with considerable nerve fiber loss at the time of diagnosis because of unsuspected hyperglycemia in preceding years. Reversal of established neuropathy with strict glycemic control is not certain to occur, even if maintained for many years. Co-morbid disease often interferes with strict management of type 2 diabetes. Even among those with type 1 diabetes, a minority of patients are successful in maintaining prolonged euglycemia.

TAK-128 is a novel synthetic compound being developed as a treatment for diabetic neuropathy. Subjects participating in this study successfully completed Protocol 01-04-TL-128-003, and earlier study of TAK-128.

02

Conditions studied

  • Diabetic Neuropathies

Browse trials for

Keywords

  • Diabetic Mononeuropathy
  • Diabetic Neuralgia
  • Mononeuropathy, Diabetic
  • Neuralgia, Diabetic
  • Diabetic Polyneuropathy
  • Drug Therapy
03

In context

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

This study's enrollment of 221 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.

Browse Diabetic Neuropathies studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has successfully completed protocol 01-04-TL-128-003.
  • Female subjects of must be nonpregnant, nonlactating and on an acceptable form of .
  • Must be in good health at Enrollment, as determined by a physician at the Month 6 Visit of Protocol 01-04-TL-128-003 (ie, via medical history and physical examination).
  • Has clinical laboratory evaluations within the normal reference range for the testing laboratory, unless the results are deemed not by the investigator or sponsor, at the Month 6 Visit of Protocol 01-04-TL-128-003.
  • Has a creatinine level less than or equal to 2 mg/dL or 176.8 umol/L.
  • The subject is willing to follow an American Diabetes Association or similar recommended dietary regimen.

Exclusion criteria

Exclusion Criteria:

  • Has developed other neuropathies due to causes other than diabetes such as alcohol abuse liver or renal disease, uremia, toxic exposure, genetic factors, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders (included treated or untreated pernicious anemia).
  • Has a systolic blood pressure greater than 160 mm HG or diastolic blood pressure is greater than 95 mm HG.
  • The subject has an level of greater than 1.5 times the , active liver disease, or jaundice.
  • Has a significant, actively treated or unstable pulmonary, cardiovascular, gastrointestinal, hepatic, hematologic, musculoskeletal, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) disease.
  • Cannot use any of the following prescription medications throughout the duration of the study, including:

    • Lipoic acid.
    • Linolenic acid (primrose oil).
    • Inositol.
    • Topiramate.
    • Acetyl-L-Carnitine.
    • Nerve growth factors.
    • Capsaicin.
  • Has any other serious disease or condition at the Month 6 Visit of Protocol 01-04-TL-128-003 or at the Baseline/Rollover Visit that might affect or make it difficult to successfully manage and follow the subject according to the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    TAK-128 100 mg QD

    Drug: TAK-128

Interventions

  • DrugTAK-128

    TAK-128 100 mg tablet, orally, once daily for up to 1 year.

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events, vital signs and physical examination findings.

    Time frame: At each visit

  2. Clinical Laboratory Tests (Hematology, Chemistry and Urinalysis).

    Time frame: At each visit

  3. Electrocardiogram results.

    Time frame: At each visit

  4. Weight.

    Time frame: At each visit

Secondary outcomes

  1. Change from Baseline in composite nerve conduction velocities (Electrophysiologic Studies).

    Time frame: Months 6 and 12 or Final Visit

  2. Change from Baseline in the electrophysiologic parameters for individual nerves, including amplitudes (Nerve Conduction Studies).

    Time frame: Months 6 and 12 or Final Visit

  3. Change from Baseline in vibration perception threshold measurements (Quantitative Sensory Testing).

    Time frame: Month 3, 6, 9 and 12 or Final Visit

  4. Change from Baseline in neurological examination (Clinical Neurologic Examination).

    Time frame: Month 3, 6, 9 and 12 or Final Visit

  5. Change from Baseline in pain scores (Short-Form McGill Pain Questionnaire).

    Time frame: Month 3, 6, 9 and 12 or Final Visit

  6. Change from Baseline in quality of life index as assessed by the Short-Form, 36-Item Health Survey.

    Time frame: Month 3, 6, 9 and 12 or Final Visit

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2008
First posted
Sep 19, 2008
Start
Sep 2005
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Last update
Feb 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00756041
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 19, 2008
Start date
Sep 2005
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Feb 28, 2012

Study contacts

Sr. Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion